Cedars-Sinai Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Cedars-Sinai Medical Center sits in the top decile of US sponsors by registered trial count (#106 of 15,742 sponsors by registered trial count).
Cedars-Sinai Medical Center: 339 sponsored US clinical trials, 70 recruiting.
Cedars-Sinai Medical Center sponsors 339 registered US clinical trials on ClinicalTrials.gov, 70 of them currently recruiting, and 180 completed. 42 of these trials are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bladder Cancer, with 6 trials.
Top-decile sponsor footprint
Cedars-Sinai Medical Center ranks in the top decile of sponsors by registered trial count (#106 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
180 of 230 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
339 total, page 7 of 7
Evaluation of Outcomes of DFine StabiliT Kyphoplasty in Vertebral Compression Fractures Due to Osteoporosis
NCT01839682
CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction
NCT00893360
Pilot Study - Impact of Traditional Acupuncture on Menopause
NCT00950482
Cortisol Levels on Menopausal Symptoms - Ancillary (Addendum) Study to Protocol 16997
NCT00950781
Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
NCT00915954
Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder
NCT00836069
Allopurinol Maintenance Study for Bipolar Disorder
NCT00732251
Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress Disorder
NCT00815204
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
NCT00672009
Allopurinol Add-on Treatment for Refractory Mania
NCT00643123
Memory Disorders Registry
NCT00654563
The Optimum Time for Preoxygenation Based on Body Mass Index
NCT01114932
Ultrasound Guided Octreotide LAR Injection in Acromegaly
NCT00552071
Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma
NCT00576641
Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder
NCT00572377
Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients
NCT00576446
Microvascular Coronary Disease In Women: Impact Of Ranolazine
NCT00570089
Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study
NCT03411291
Adenosine Dual Source Computed Tomography (CT) Versus Adenosine Single Photon Emission Computed Tomography (SPECT)
NCT00892307
Omega-3 Fatty Acids for Treatment of Depression in Adolescents
NCT00658476
Diffusion Tensor (Magnetic Resonance) Imaging and Tractography in Herniation of the Cervical Spine
NCT00599183
Omega-3 Fatty Acids for Treating Adults With Major Depression
NCT00517036
Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients
NCT00574197
Combination Lexapro and Massage for Treatment of Depression in Older Adults
NCT00643162
Effectiveness of a Barbershop-Based Program to Improve High Blood Pressure Control and Awareness in Black Men
NCT00325533
The Effects of Red Wine and White Wine on Blood Estrogen and Progesterone Levels
NCT00572351
The Effects of Traditional Acupuncture on Mechanisms of Coronary Heart Disease
NCT00570024
Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation
NCT00642655
Randomized Evaluation of Intracoronary Transplantation of Bone Marrow Stem Cells in Myocardial Infarction
NCT00874354
Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease
NCT00829595
Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women
NCT00572858
Women's Health Research Registry
NCT00574314
Benefit of Elevation of HDL-C in Women
NCT01921010
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
NCT00064376
Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women
NCT00590629
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
NCT00576537
Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research (EISNER)
NCT00927693
Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study
NCT00600106
Reproductive Hormones And Pre-Clinical Cardiovascular Disease (CVD) In Women
NCT00574535
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 43 |
| Phase 2 | 40 |
| Phase 3 | 9 |
| Phase 4 | 33 |
What is open in the Cedars-Sinai Medical Center pipeline
70 recruiting of 339 indexed (21% open); 180 completed (53%).
Phase mix: 42 late (III/IV) vs 83 early (I/II) (early-phase heavy).
Top condition: Bladder Cancer (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Cedars-Sinai Medical Center: open-pipeline peers nationwide
Peers matched on 339 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
Cedars-Sinai Medical Center sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 339 trials (± recruiting share)
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Ohio State University Comprehensive Cancer Center · 341 trials · 23% recruiting
- Children's Oncology Group · 342 trials · 10% recruiting
- National Institute of Mental Health (NIMH) · 343 trials · 12% recruiting
Sponsors near 21% open enrollment (± trial volume)
- University of Colorado, Denver · 21% recruiting · 1,283 trials
- Craig Hospital · 21% recruiting · 29 trials
- W.L.Gore & Associates · 21% recruiting · 53 trials
- Georgia Institute of Technology · 21% recruiting · 24 trials
Related
What to do with this Cedars-Sinai Medical Center page
339 registered trials is a research-attention snapshot, not an endorsement of Cedars-Sinai Medical Center or any single study.
- 70 of Cedars-Sinai Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Bladder Cancer is the condition Cedars-Sinai Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bladder Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cedars-Sinai Medical Center pipeline card: 339 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.